Tumor-induced immunosuppression is an important reason for evading immune surveillance attack.407 Immune checkpoint therapy (ICT) strategies targeting PD-1 and CTLA-4 can reverse tumor immunosuppression to a certain extent and achieve better therapeutic effects, but the clinical response is still low. This evidence concerns the gene CTLA4 and neoplasm.